Bioarctic was behind the early development of Leqembi (lecanemab), the first approved drug proven to slow the progression of Alzheimer's disease, but the company is also running several projects within other neurodegenerative diseases. One of these is exidavnemab, which is being developed as a new disease-modifying treatment for multiple system atrophy (MSA) and Parkinson's disease.
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
Advertisement
BREAKING